{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"title":"disease-free by time of surgery"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"11"}]}],"title":"partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"34"}]}],"title":"stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"88"}]}],"title":"progressive disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]}],"title":"did not receive treatment"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"13"}]}],"title":"could not be evaluated"}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"description":"RECIST 1.0 was used to evaluate response","groups":[{"description":"etopodide, doxorubicin, cisplatin and mitotane\n\nEtoposide\n\nDoxorubicin\n\nCisplatin\n\nMitotane\n\nparticipants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)","id":"OG000","title":"EDP-M"},{"description":"streptozotocin and mitotane\n\nStreptozotocin\n\nMitotane\n\nparticipants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)","id":"OG001","title":"Sz-M"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"every 8 weeks up to 5 years","title":"Best Overall Response Rate","type":"SECONDARY","unitOfMeasure":"participants"}